Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BLINATUMOMAB Cause Neoplasm progression? 53 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 53 reports of Neoplasm progression have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.6% of all adverse event reports for BLINATUMOMAB.

53
Reports of Neoplasm progression with BLINATUMOMAB
0.6%
of all BLINATUMOMAB reports
14
Deaths
17
Hospitalizations

How Dangerous Is Neoplasm progression From BLINATUMOMAB?

Of the 53 reports, 14 (26.4%) resulted in death, 17 (32.1%) required hospitalization, and 1 (1.9%) were considered life-threatening.

Is Neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 53 reports have been filed with the FAERS database.

What Other Side Effects Does BLINATUMOMAB Cause?

Pyrexia (1,064) Acute lymphocytic leukaemia recurrent (977) Cytokine release syndrome (952) Off label use (590) Death (588) Neurotoxicity (530) Drug ineffective (345) Headache (335) Neutropenia (265) Febrile neutropenia (262)

What Other Drugs Cause Neoplasm progression?

PALBOCICLIB (10,885) SUNITINIB MALATE (1,920) CYCLOPHOSPHAMIDE (1,588) CARBOPLATIN (1,370) AXITINIB (1,315) DOXORUBICIN (1,276) LETROZOLE (1,225) PACLITAXEL (1,180) CRIZOTINIB (1,161) VINCRISTINE (1,106)

Which BLINATUMOMAB Alternatives Have Lower Neoplasm progression Risk?

BLINATUMOMAB vs BLONANSERIN BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1 BLINATUMOMAB vs BOCEPREVIR BLINATUMOMAB vs BOCOCIZUMAB BLINATUMOMAB vs BONIVA

Related Pages

BLINATUMOMAB Full Profile All Neoplasm progression Reports All Drugs Causing Neoplasm progression BLINATUMOMAB Demographics